Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.
Kunihiko UmekitaYayoi HashibaKosho IwaoChihiro IwaoMasatoshi KimuraYumi KariyaKazuyoshi KuboShunichi MiyauchiRisa KudouYuki RikitakeKatoko TakajoTakeshi KawaguchiMotohiro MatsudaIchiro TakajoEisuke InoueToshihiko HidakaAkihiko OkayamaPublished in: PloS one (2020)
HTLV-1 infection affects T-SPOT.TB assay results in RA patients. Assay results in HTLV-1 endemic regions should be interpreted with caution when screening for latent tuberculosis infection before initiation of biologic therapy.
Keyphrases
- rheumatoid arthritis patients
- mycobacterium tuberculosis
- high throughput
- rheumatoid arthritis
- disease activity
- end stage renal disease
- case control
- endothelial cells
- chronic kidney disease
- newly diagnosed
- prognostic factors
- acute myeloid leukemia
- pulmonary tuberculosis
- hiv aids
- induced pluripotent stem cells
- human immunodeficiency virus
- hepatitis c virus
- single cell
- patient reported
- systemic sclerosis
- ankylosing spondylitis
- antiretroviral therapy